Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO), and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most ...

A direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention the side effects of the drugs.

Novo Nordisk (NYSE: NVO) stock is in a funk. Monday's decline probably owes to rival GLP-1 company Hims & Hers Health running ...

Hims & Hers hit the bullseye with its Super Bowl ad—it sparked a lot of attention from consumers. | Hims & Hers hit the ...

By: Katie Karlson and Madeline Darby Super Bowl commercials have been a cultural phenomenon for years. However, this year, one commercial sparked widespread controversy and a heated debate about the ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...